Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UP79
UPID:
ATS8_HUMAN
Alternative names:
METH-2; METH-8
Alternative UPACC:
Q9UP79; Q9NZS0
Background:
A disintegrin and metalloproteinase with thrombospondin motifs 8 (ADAMTS8), also known as METH-2 and METH-8, plays a crucial role in the regulation of angiogenesis, the process by which new blood vessels form from pre-existing vessels. Its anti-angiogenic properties suggest a pivotal function in controlling vascular growth and stability.
Therapeutic significance:
Understanding the role of ADAMTS8 could open doors to potential therapeutic strategies. Its ability to inhibit angiogenesis positions it as a target of interest in the development of treatments for diseases characterized by abnormal vessel growth, such as certain cancers and retinopathies.